Actively Recruiting

Phase 3
Age: 10Years - 17Years
All Genders
NCT05303064

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

Led by Alkermes, Inc. · Updated on 2026-05-06

220

Participants Needed

47

Research Sites

217 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

CONDITIONS

Official Title

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

Who Can Participate

Age: 10Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Subjects aged 13 to 17 years with schizophrenia or aged 10 to 17 years with bipolar I disorder diagnosed by DSM-5 criteria
  • Outpatient or able to be treated as outpatient by study Week 2
  • Reliable family or guardian support for outpatient management
  • Currently treated with olanzapine or inadequate response to other antipsychotics
  • Not a danger to self or others by investigator judgment
Not Eligible

You will not qualify if you...

  • Major depressive episode or other neuropsychiatric diagnosis interfering with study participation
  • History of seizure disorder (except febrile seizures), severe head trauma with loss of consciousness within 12 months, or other significant neurological condition in past 12 months
  • Current suicide risk as assessed by investigator or C-SSRS
  • Received olanzapine for 14 days or more in the month prior or poor response to olanzapine
  • Use of opioid agonists within 14 days (or 30 days for long-acting) prior to screening
  • Anticipated opioid use during study (e.g., planned surgery)
  • Use of opioid antagonists within 60 days prior to screening
  • Use of long-acting injectable antipsychotics within 3 injection cycles prior to screening
  • BMI percentile over 98th or under 5th
  • Diagnosis of diabetes mellitus or prediabetes (HbA1c ≥ 6%) at screening
  • Started smoking cessation or weight management program or major diet/exercise changes within 6 months or 6 weeks prior to screening
  • Participation in another investigational study within 30 days prior to screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 47 locations

1

Alkermes Investigator Site

Dothan, Alabama, United States, 36303

Actively Recruiting

2

Alkermes Investigator Site

Little Rock, Arkansas, United States, 72204

Actively Recruiting

3

Alkermes Investigator Site

Encino, California, United States, 91316

Withdrawn

4

Alkermes Investigator Site

Stanford, California, United States, 94305

Actively Recruiting

5

Alkermes Investigator Site

Upland, California, United States, 91786

Withdrawn

6

Alkermes Investigator Site

Colorado Springs, Colorado, United States, 80910

Withdrawn

7

Alkermes Investigator Site

Denver, Colorado, United States, 80202

Active, Not Recruiting

8

Alkermes Investigator Site

Hartford, Connecticut, United States, 06106

Withdrawn

9

Alkermes Investigator Site

Washington D.C., District of Columbia, United States, 20010

Actively Recruiting

10

Alkermes Investigator Site

Miami, Florida, United States, 33155

Withdrawn

11

Alkermes Investigator Site

Miami Lakes, Florida, United States, 33016

Actively Recruiting

12

Alkermes Investigator Site

Decatur, Georgia, United States, 30030

Actively Recruiting

13

Alkermes Investigator Site

Chicago, Illinois, United States, 60611

Actively Recruiting

14

Alkermes Investigator Site

Indianapolis, Indiana, United States, 46202

Actively Recruiting

15

Alkermes Investigator Site

Saint Charles, Missouri, United States, 63304

Actively Recruiting

16

Alkermes Investigator Site

Lincoln, Nebraska, United States, 68526

Actively Recruiting

17

Alkermes Investigator Site

Omaha, Nebraska, United States, 68198

Withdrawn

18

Alkermes Investigator Site

Paramus, New Jersey, United States, 07652

Withdrawn

19

Alkermes Investigator Site

New York, New York, United States, 10016

Not Yet Recruiting

20

Alkermes Investigational Site

Kinston, North Carolina, United States, 28504

Withdrawn

21

Alkermes Investigator Site

Cincinnati, Ohio, United States, 45219

Actively Recruiting

22

Alkermes Investigator Site

West Chester, Ohio, United States, 45069

Actively Recruiting

23

Alkermes Investigator Site

DeSoto, Texas, United States, 75115

Terminated

24

Alkermes Investigator Site

Fort Worth, Texas, United States, 76104

Withdrawn

25

Alkermes Investigational Site

Richmond, Virginia, United States, 23220

Actively Recruiting

26

Alkermes Investigator Site

Everett, Washington, United States, 98201

Actively Recruiting

27

Alkermes Investigator Site

La Plata, Buenos Aires, Argentina, 1900

Actively Recruiting

28

Alkermes Investigator Site

La Plata, Buenos Aires, Argentina, C1199ABB

Actively Recruiting

29

Alkermes Investigator Site

Buenos Aires, Argentina, C1133AAH

Actively Recruiting

30

Alkermes Investigator Site

Córdoba, Argentina, X5003DCE

Actively Recruiting

31

Alkermes Investigator Site

Mendoza, Argentina, 5500

Actively Recruiting

32

Alkermes Investigator Site

Fortaleza, Ceará, Brazil, 60430-140

Actively Recruiting

33

Alkermes Investigator Site

Curitiba, Paraná, Brazil, 80240-280

Actively Recruiting

34

Alkermes Investigator Site

Goiânia, Brazil, 74093-040

Actively Recruiting

35

Alkermes Investigator Site

Rio de Janeiro, Brazil, 22270-060

Actively Recruiting

36

Alkermes Investigator Site

São Paulo, Brazil, 01228-000

Actively Recruiting

37

Alkermes Investigator Site

São Paulo, Brazil, 05403-010

Actively Recruiting

38

Alkermes Investigator Site

Barranquilla, Colombia, 110121

Actively Recruiting

39

Alkermes Investigator Site

Bello, Colombia, 51053

Actively Recruiting

40

Alkermes Investigator Site

Bogotá, Colombia, 111166

Actively Recruiting

41

Alkermes Investigator Site

Bogotá, Colombia, 80020

Actively Recruiting

42

Alkermes Investigator Site

Pereira, Colombia, 660003

Actively Recruiting

43

Alkermes Investigator Site

Culiacán, Mexico, 80230

Actively Recruiting

44

Alkermes Investigator Site

Estado de México, Mexico, C.P. 07000

Actively Recruiting

45

Alkermes Investigator Site

León, Mexico, 37000

Actively Recruiting

46

Alkermes Investigator Site

Monterrey, Mexico, 64620

Actively Recruiting

47

Alkermes Investigator Site

Monterrey, Mexico, 64710

Actively Recruiting

Loading map...

Research Team

G

Global Clinical Services

CONTACT

G

Global Clinical Services

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here